GSK seeks to boost oncology repertoire with $5.1bn acquisition
03-12-2018
gevende / iStockphoto.com
UK headquartered GSK has made another move in the oncology space, signing a potential €3.7 billion ($3.3 billion) immunotherapy deal with Germany-based Merck KGaA.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Merck KGaA, Germany, UK, Americas, Europe: big pharma, genetics